Promoting safe and effective biosimilars can lead to more affordable biologic medicines
Biosimilar entry led to an average decrease in the cost of therapy from 17% in the Human Growth Hormone (HGH) market to 39% in the G-CSF market throughout the EU
Note: Countries included: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Ireland, Italy, Norway, Poland, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK. HGH = Human Growth Hormone (somatropin), EPO = Erythropoietin, G-CSF = Granulocyte Colony-Stimulating Factor.
Source: Health Advances analysis; IMS Institute for Healthcare Informatics 2014 Assessing biosimilar uptake and competition in European markets.